## Clinical Scenario Analysis The patient has **Type 2 lepra reaction (Erythema Nodosum Leprosum, ENL)**, characterized by: - Acute onset of painful nodules and systemic symptoms (fever) - Worsening of skin lesions during treatment - Occurs in **lepromatous (LL) and borderline lepromatous (BL) cases** only - Typically appears during or shortly after starting MDT (immune complex-mediated reaction) ## Key Point: **Type 2 lepra reaction is an immune complex-mediated reaction that requires corticosteroid therapy (prednisolone) in addition to continuation of MDT.** The MDT regimen itself is NOT changed. ## Management Algorithm for ENL ```mermaid flowchart TD A[LL/BL on MDT with acute nodules + fever]:::outcome --> B{Diagnose ENL}:::decision B -->|Confirmed| C[Start prednisolone 0.5-1 mg/kg/day]:::action C --> D[Continue same MDT regimen]:::action D --> E[Taper prednisolone over 3-6 months]:::action E --> F[Monitor for resolution]:::outcome B -->|Severe/refractory| G[Add thalidomide 100-400 mg/day]:::action G --> H[Reduce prednisolone dose]:::action ``` ## High-Yield: - **ENL is NOT drug resistance** — AFB counts may remain high or decrease slowly because the reaction is immune-mediated, not due to treatment failure - **MDT is continued unchanged** — stopping or switching regimens is harmful - **Prednisolone is the first-line anti-inflammatory agent** for ENL - **Thalidomide** is reserved for prednisolone-dependent or refractory cases (contraindicated in pregnancy) ## Clinical Pearl: ENL occurs in 50% of LL patients and 10% of BL patients. It can develop during treatment or even months after completion. The key is to recognize it as an **immune phenomenon** requiring immunosuppression, not a sign of treatment failure.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.